Expert Interview
A look at the new data from the Phase 2 XPORT-MF-035 trial evaluating Karyopharm's selinexor in a heavily pretreated myelofibrosis population.
Ticker(s): KPTIInstitution: Vanderbilt University Medical Center
- Assistant Professor of Medicine, Hematology/Oncology at Vanderbilt University Medical Center.
- Manages 60 patients with Myelofibrosis.
- Completed fellowship in experimental therapeutics from Taussig Cancer institute in 2021 and research focuses on cancer biology.
How would you describe the current treatment landscape for myelofibrosis, particularly in patients who have progressed on or are intolerant to JAK inhibitors?
Added By: sara_adminWhat are your impressions of the efficacy and safety data from the Phase 2 XPORT-MF-035 trial evaluating selinexor monotherapy in heavily pretreated myelofibrosis patients?
Added By: sara_adminIn your view, where might selinexor fit into the treatment algorithm if approved—would it be more appropriate as a bridge therapy, salvage option, or earlier-line agent in specific patient subgroups?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
